The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kucheryavenko A.F.

Volgograd State Medical University», Volgograd, Russia

Spasov A.A.

Volgograd State Medical University», Volgograd, Russia

Naumenko L.V.

Volgograd State Medical University», Volgograd, Russia

The influence of the new hypoglycemic agent limiglidol on the parameters of hemostasis in experimental diabetes mellitus

Authors:

Kucheryavenko A.F., Spasov A.A., Naumenko L.V.

More about the authors

Journal: Problems of Endocrinology. 2015;61(1): 51‑56

Read: 624 times


To cite this article:

Kucheryavenko AF, Spasov AA, Naumenko LV. The influence of the new hypoglycemic agent limiglidol on the parameters of hemostasis in experimental diabetes mellitus. Problems of Endocrinology. 2015;61(1):51‑56. (In Russ.)
https://doi.org/10.14341/probl201561151-56

Recommended articles:
Clinical and gene­tic asso­ciations in patients with non-cardioembolic ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):12-19

References:

  1. Lopes RD. Antiplatelet agents in cardiovascular disease. J. Thromb. Thrombolysis. 2011;31(3):306-309. doi: 10.1007/s11239-011-0558-9
  2. Morel O, Kessler L, Ohlmann P, Bareiss P. Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis. 2010;212(2):367-376. doi: 10.1016/j.atherosclerosis.2010.03.019
  3. Dedov II, Shestakova MV. Relevance of results of the ADVANCE study for diabetes control in Russia. Diabetes mellitus. 2009;12(2):4-5. doi: 10.14341/2072-0351-5388
  4. Tamariz LJ, Young JH, Pankow JS, et al. Blood Viscosity and Hematocrit as Risk Factors for Type 2 Diabetes Mellitus: The Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 2008;168(10):1153-1160. doi: 10.1093/aje/kwn243
  5. Singh M, Shin S. Changes in erythrocyte aggregation and deformability in diabetes mellitus: a brief review. Indian J. Exp. Biol. 2009;47(1):7-15.
  6. Murav’ev AV, Cheporov SV. Gemoreologiya (eksperimental’nye i klinicheskie aspekty reologii krovi). Yaroslavl’: YaGPU; 2009.
  7. Hagedorn I, Vogtle T, Nieswandt B. Arterial thrombus formation. Novel mechanisms and targets. Hamostaseologie. 2010;30(3):127-135.
  8. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease. 2008;5(2):138. doi: 10.3132/dvdr.2008.023.
  9. 1,2-a]бензимидазолов. // Химико-фармацевтический журнал. – 2002. – Т. 36. – №10 – С. 12-17. [Anisimova VA, Spasov AA, Kucheryavenko AF, et al. Synthesis and pharmacological activity of 2-(hetaryl)imidazo[1,2-a]benzimidazoles. Pharm. Chem. J. 2002;36(10):528-534. doi: 10.1023/a:1022498224975
  10. Kucheryavenko AF, Cpasov AA, Petrov VI, Anisimova VA. Antiagregantnaya aktivnost’ novogo proizvodnogo benzimidazola. Bull. Exp. Biol. Med. 2013;156(12):760-762.
  11. 1, 2-abenzimidazole dihydrochlorides. Pharm. Chem. J. 2009;43(9):491-494. doi: 10.1007/s11094-009-0340-x 
  12. Spasov AA, Petrov VI, Anisimova VA. Novoe gipoglikemicheskoe sredstvo s gemoreologicheskimi svoystvami. Proceedings of IV Russian diabetology congress. Moscow; 2008.
  13. Chougale AD, Panaskar SN, Gurao PM, Arvindekar AU. Optimization of Alloxan Dose is Essential to Induce Stable Diabetes for Prolonged Period. Asian Journal of Biochemistry. 2007;2(6):402-408. doi: 10.3923/ajb.2007.402.408
  14. Elenga A, Shtrygol’ SY, Nazarov SB, Kinkembo N. The effect of a dietary mineral intake on the hemorheological effects of trental in rats with experimental circulatory insufficiency. Eksperimental’naia i klinicheskaia farmakologiia. 2002;65(1):37-40.
  15. Gabbasov ZA, Popov EG, Gavrilova IY., et al. Novyy vysokochuvstvitel’nyy metod analiza agregatsii trombotsitov. Laboratornoe delo. 1989;(10):15-18.
  16. Dobrovol’skiy NA, Lopukhin YuM, Parfenov AS, Peshkov AV. Analizator vyazkosti krovi. Reologicheskie issledovaniya v meditsine. Moscow: RAMS; 1997.
  17. Parfenov AS, Peshkov AV, Dobrovol’skiy NA. Analizator krovi reologicheskiy AKR-2. Opredelenie reologicheskikh svoystv krovi. (manual) Moscow: SRI Physical-Chemical Medicine; 1994.
  18. Guglielmi G, Viñuela F, Dion J, Duckwiler G. Electrothrombosis of saccular aneurysms via endovascular approach. J. Neurosurg. 1991;75(1):8-14. doi: 10.3171/jns.1991.75.1.0008.
  19. Cerbone AM, Macarone-Palmieri N, Saldalamacchia G, et al. Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetol. 2008;46(4):253-261. doi: 10.1007/s00592-008-0079-y
  20. Spasov AA, Kucheryavenko AF, Maistrenko BP. Antiaggregant Activity of Hypoglycemic Drugs. Eksperimental’naia i klinicheskaia farmakologiia. 2009;72(6):27-29.
  21. Ambrosi P, Villani P, Bouvenot G. Antiplatelet therapy for primary prevention in diabetes. Diabetes Metab. 2006;32:2S52-52S56. doi: 10.1016/s1262-3636(06)70487-6.
  22. Kudryashova MV, Dovgalyuk YV, Mishina IE, et al. Possibilities of Correction of Rheological Properties of the Blood and Free Radical Processess in Patients With Acute Myocardial Infarction Combined With Type 2 Diabetes Mellitus. Kardiologiia. 2010;50(5):9-12.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.